Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Bonomi Discusses Liquid Biopsies in Lung Cancer

October 3rd 2017

Philip D. Bonomi, MD, The Alice Pirie Wirtz Professor of Medical Oncology, Rush Medical College, medical oncologist, Rush University Medical Center, discusses liquid biopsies in lung cancer.

FDA Approves Higher-Dose Tablet of Brigatinib for NSCLC

October 3rd 2017

The FDA has approved a supplemental new drug application for the use of 180-mg tablets of brigatinib for the treatment of patients with non–small cell lung cancer.

Lead FLAURA Researcher Discusses Frontline Osimertinib in EGFR+ NSCLC

September 29th 2017

Suresh A. Ramalingam, MD, discusses the practice-changing FLAURA findings and his thoughts on sequencing should the FDA approve osimertinib in the frontline setting of non-small cell lung cancer.

Dr. Fidler Discusses Osimertinib in EGFR-Mutated Lung Cancer

September 28th 2017

Mary Jo Fidler, MD, associate professor, medical oncology, hematology, internal medicine, Rush University Medical Center, discusses osimertinib (Tagrisso) in patients with EGFR T790M-positive non–small cell lung cancer.

Dr. Patel on Combination Chemotherapy and Immunotherapy in Lung Cancer

September 28th 2017

Jyoti Patel, MD, professor of medicine, director, Thoracic Oncology, University of Chicago School of Medicine, discusses combination chemotherapy and immunotherapy in patients with lung cancer.

Future Directions in NSCLC Immuno-Oncology Research

September 28th 2017

Immuno-Oncology Combination Therapy in NSCLC

September 28th 2017

Promising Immunotherapy Agents for NSCLC

September 28th 2017

PACIFIC Trial: Durvalumab for Stage 3 NSCLC

September 28th 2017

Immunotherapy for Management of Stage 3B NSCLC

September 28th 2017

Immunotherapy Toxicity Management in NSCLC

September 28th 2017

Treatment for NSCLC After Progression on Immunotherapy

September 28th 2017

Combination Approaches for Second-Line Therapy for NSCLC

September 28th 2017

The Role of Mutation Burden as a Biomarker in NSCLC

September 28th 2017

Immunotherapy for Relapsed or Refractory NSCLC

September 28th 2017

Isolated Progression of NSCLC on Immunotherapy

September 28th 2017

The Potential for IO Use as Maintenance Therapy in NSCLC

September 28th 2017

Duration of Upfront Immunotherapy for NSCLC

September 28th 2017

Patient Selection for Upfront Immunotherapy in NSCLC

September 28th 2017

Upfront PD-L1 Blockade in Newly Diagnosed NSCLC

September 28th 2017